Lupin gains with YL Biologics receiving PMDA approval for Etanercept biosimilar in Japan

26 Mar 2019 Evaluate

Lupin is currently trading at Rs. 734.85, up by 5.75 points or 0.79% from its previous closing of Rs. 729.10 on the BSE.

The scrip opened at Rs. 735.00 and has touched a high and low of Rs. 738.50 and Rs. 731.75 respectively. So far 31159 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 986.00 on 10-Sep-2018 and a 52 week low of Rs. 723.55 on 15-May-2018.

Last one week high and low of the scrip stood at Rs. 759.20 and Rs. 726.00 respectively. The current market cap of the company is Rs. 33250.73 crore.

The promoters holding in the company stood at 46.98%, while Institutions and Non-Institutions held 38.84% and 14.18% respectively.

YL Biologics (YLB), a joint venture between Lupin's subsidiary Lupin Atlantis Holdings SA (LAHSA) and Yoshindo Inc. in Japan, and Lupin (through its Japanese subsidiary, Kyowa Pharmaceutical Industry) have received an approval from Pharmaceutical and Medical Devices Agency (PMDA) to manufacture and sell their biosimilar Etanercept in Japan. The approval to treat moderate to severe Rheumatoid Arthritis (RA) and Juvenile Idiopathic Arthritis was received on March 26, 2019.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2082.60 27.55 (1.34%)
11-Dec-2025 14:11 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1802.00
Dr. Reddys Lab 1271.40
Cipla 1509.65
Zydus Lifesciences 924.80
Lupin 2082.60
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×